

Electronic Acknowledgement Receipt

EFS ID:	1225213
Application Number:	10536780
Confirmation Number:	4292
Title of Invention:	Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function
First Named Inventor:	Jose Esteve-Soler
Customer Number:	2512
Filer:	GEZA C ZIEGLER JR/Carolina Rodriguez
Filer Authorized By:	GEZA C ZIEGLER JR
Attorney Docket Number:	785-012247-US(PAR)
Receipt Date:	28-SEP-2006
Filing Date:	
Time Stamp:	15:48:59
Application Type:	U.S. National Stage under 35 USC 371
International Application Number:	

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 730
RAM confirmation Number	169
Deposit Account	161350
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Transmittal letter	Transmittal.pdf	214659	no	4
Warnings:					
Information:					
2	Oath or Declaration filed	Executed_Declaration.pdf	140205	no	4
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Filed	IDS_PTO1449.pdf	161129	no	4
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
4	NPL Documents	Consequences.pdf	798577	no	9
Warnings:					
Information:					
5	NPL Documents	NitricOxide.pdf	2393678	no	18
Warnings:					
Information:					
6	NPL Documents	HumanCoronary.pdf	726888	no	8
Warnings:					
Information:					
7	NPL Documents	Endothelium.pdf	670245	no	8
Warnings:					
Information:					
8	NPL Documents	EndotheliumDependent.pdf	950682	no	10
Warnings:					
Information:					

9	NPL Documents	Characterization.pdf	859349	no	8
Warnings:					
Information:					
10	NPL Documents	Pharmacological.pdf	1179958	no	12
Warnings:					
Information:					
11	NPL Documents	Effects.pdf	604553	no	6
Warnings:					
Information:					
12	NPL Documents	InVitro.pdf	333880	no	4
Warnings:					
Information:					
13	NPL Documents	Dobesilate.pdf	752562	no	7
Warnings:					
Information:					
14	Fee Worksheet (PTO-875)	fee-info.pdf	8540	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			9794905		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					